JP2001508430A5 - - Google Patents

Download PDF

Info

Publication number
JP2001508430A5
JP2001508430A5 JP1998530400A JP53040098A JP2001508430A5 JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5 JP 1998530400 A JP1998530400 A JP 1998530400A JP 53040098 A JP53040098 A JP 53040098A JP 2001508430 A5 JP2001508430 A5 JP 2001508430A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998530400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001508430A (ja
Filing date
Publication date
Priority claimed from US08/779,767 external-priority patent/US6737057B1/en
Application filed filed Critical
Publication of JP2001508430A publication Critical patent/JP2001508430A/ja
Publication of JP2001508430A5 publication Critical patent/JP2001508430A5/ja
Ceased legal-status Critical Current

Links

JP53040098A 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法 Ceased JP2001508430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/779,767 1997-01-07
US08/779,767 US6737057B1 (en) 1997-01-07 1997-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
PCT/US1998/000520 WO1998030706A1 (en) 1997-01-07 1998-01-07 Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors

Publications (2)

Publication Number Publication Date
JP2001508430A JP2001508430A (ja) 2001-06-26
JP2001508430A5 true JP2001508430A5 (https=) 2005-09-08

Family

ID=25117492

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53040098A Ceased JP2001508430A (ja) 1997-01-07 1998-01-07 免疫抑制因子のエンドサイトーシスによる提示のための化合物、組成物及び方法

Country Status (6)

Country Link
US (2) US6737057B1 (https=)
EP (1) EP1012308A1 (https=)
JP (1) JP2001508430A (https=)
AU (1) AU744885B2 (https=)
CA (1) CA2277582A1 (https=)
WO (1) WO1998030706A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
AU5090899A (en) * 1998-07-06 2000-01-24 University Of Tennessee Research Corporation, The Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
EP1104456A1 (en) * 1998-08-10 2001-06-06 Chiron Corporation Engineered antigen-presenting cells expressing an array of antigens and uses thereof
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
MXPA02001417A (es) 1999-08-09 2002-08-12 Lexigen Pharm Corp Complejos multiples de citosina-anticuerpo.
EP1598370A3 (en) * 1999-10-27 2006-05-10 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of autoimmune and transplant related host versus graft conditions
WO2001036448A2 (en) * 1999-10-27 2001-05-25 Cel-Sci Corporation Preparation and composition of peptides useful for treatment of autoimmune and transplant related graft versus host conditions
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
CA2416656A1 (en) * 2000-06-05 2002-04-04 University Of Tennessee Corporation Compositions and methods for the endocytic presentation of immunosuppressive factors
KR20030064275A (ko) 2000-06-29 2003-07-31 메르크 파텐트 게엠베하 면역싸이토카인 흡수 증강제와의 조합 치료에 의한항체-싸이토카인 융합 단백질 매개 면역 반응 증강
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
EP1383785B1 (en) 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
EP1499346B1 (en) 2002-04-09 2008-01-02 The Curators Of The University Of Missouri Treatment of type 1 diabetes before and after expression of predisposition markers
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
US8603472B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603471B2 (en) * 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
AU2003232872A1 (en) * 2002-05-27 2003-12-12 Ostergotlands Lans Landsting Method for determining immune system affecting compounds
WO2004055056A1 (en) 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
ES2305886T3 (es) 2003-12-30 2008-11-01 Merck Patent Gmbh Proteinas de fusion de il-7 con porciones de anticuerpo, su preparacion y su empleo.
RU2370276C2 (ru) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ЭРИТРОПОЭТИН СЛИТЫЙ БЕЛОК С УЛУЧШЕННОЙ ФАРМАКОКИНЕТИКОЙ
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
SE0402536D0 (sv) * 2004-10-20 2004-10-20 Therim Diagnostica Ab Immunoregulation in cancer, chronic inflammatory and autoimmune diseases
RU2437893C2 (ru) 2004-12-09 2011-12-27 Мерк Патент Гмбх Варианты il-7 со сниженной иммуногенностью
EP1875246B1 (en) * 2005-04-15 2016-10-05 CanImGuide Therapeutics AB Diagnostic method for detecting cancer by measuring amount of a cytokine like il-6
ES2608803T3 (es) 2007-05-08 2017-04-17 Canimguide Therapeutics Ab Estructuras inmunorreguladoras procedentes de proteínas naturales
SG175233A1 (en) 2009-04-22 2011-11-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
AU616338B2 (en) 1989-02-02 1991-10-24 Mato Maschinen- Und Metallwarenfabrik Curt Matthaei Gmbh & Co Kg Belt skimming device
ATE130765T1 (de) * 1989-02-24 1995-12-15 Univ California Gentechnologisch veränderte immunglobuline.
US5612035A (en) 1989-03-21 1997-03-18 The Immune Response Corporation Vaccination against diseases resulting from pathogenic responses by specific T cell populations
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK0553244T4 (da) 1990-10-05 2005-08-01 Celldex Therapeutics Inc Målrettet immunostimulering med bispecifikke reagenser
WO1993006135A1 (en) 1991-09-23 1993-04-01 Genentech, Inc. Diagnosing and treating autoimmune disorders
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
AU3220593A (en) 1991-11-19 1993-06-15 Anergen, Inc. Soluble mhc molecules and their uses
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
WO1994014847A1 (en) 1992-12-24 1994-07-07 The Regents Of The University Of California Genetically engineered immunoglobulins
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US6329499B1 (en) 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
JPH11511650A (ja) 1995-05-02 1999-10-12 アレクション・ファーマシューティカルズ・インク 改変されたミエリンタンパク質分子
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
CA2301709C (en) 1997-08-19 2011-03-01 Sofia Casares Epitope-bearing major histocompatibility complex class ii element/immunoglobulin chimeric molecules

Similar Documents

Publication Publication Date Title
JP2000509942A5 (https=)
JP2000509637A5 (https=)
JP2000507042A5 (https=)
JP2000509635A5 (https=)
JP2000509912A5 (https=)
JP2000510751A5 (https=)
JP2000509587A5 (https=)
JP2000507369A5 (https=)
JP2000507433A5 (https=)
JP2000508866A5 (https=)
JP2000510793A5 (https=)
JP2000508022A5 (https=)
JP2000508841A5 (https=)
JP2000508680A5 (https=)
JP2000509804A5 (https=)
JP2000509853A5 (https=)
JP2000509755A5 (https=)
JP2000510247A5 (https=)
JP2000510969A5 (https=)
JP2000508836A5 (https=)
JP2001513765A5 (https=)
JP2000508102A5 (https=)
JP2000509520A5 (https=)
JP2000509818A5 (https=)
JP2000507434A5 (https=)